Introduction

The American Cancer Society has released updated guidance that takes a firmer stance on prostate cancer screening. Rather than leaving the decision entirely to individual conversations between patients and doctors, the organization now directly recommends that most men begin regular screening at age 50. The shift reflects newer evidence showing that routine testing can meaningfully lower the risk of dying from the disease.

What Happened

Published in CA: A Cancer Journal for Clinicians, the new guideline replaces the 2010 version, which emphasized informed decision-making. Under the updated advice, men at average risk should undergo prostate-specific antigen (PSA) blood testing every two years from age 50 through 69. Black men and men with a strong family history are advised to begin annual screening at age 45. For men between 70 and 74, the decision becomes personal again, and routine screening is not advised for those 75 and older.

The society defines an abnormal result as a PSA level of 3 nanograms per milliliter or higher for men 69 and younger, and 6.5 nanograms per milliliter or higher for men ages 70 to 74. If an initial test comes back high, the recommendation is to repeat the test within two weeks to three months before moving to more invasive follow-up steps.

Why This Matters

Prostate cancer remains the second-leading cause of cancer death among men in the United States, trailing only lung cancer. Diagnosis rates have climbed roughly 3 percent annually from 2014 through 2022, with more late-stage cases appearing during that window. Yet when the disease is caught before it spreads, more than 99 percent of patients survive at least five years.

Experts point to long-term European data showing that men invited to regular PSA testing were about 13 percent less likely to die from prostate cancer than those who were not screened. The society also notes that modern tools such as MRI and biomarker tests help doctors avoid unnecessary biopsies and overtreatment of low-risk cancers.

Key Takeaways

  • Average-risk men: PSA screening every two years, ages 50 to 69.
  • Higher-risk men, including Black men and those with a family history: annual screening starting at age 45.
  • Men ages 70 to 74: individualized decisions with a clinician.
  • Men 75 and older: routine screening is not recommended.
  • An elevated PSA does not automatically mean cancer; it can also signal an enlarged prostate or infection.

Conclusion

The updated guidance is designed to close a gap that left many men unaware they should be tested. While insurance coverage for follow-up procedures remains uneven, the clearer recommendation may encourage more primary care doctors to offer the test and could strengthen the case for broader coverage. Men within the recommended age ranges should speak with a healthcare provider about establishing a baseline PSA level and what a screening schedule might look like for their personal risk profile.